Overview

An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients

Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label study, to evaluate the efficacy and safety of a BTK inhibitor zanubrutinib in participants with NMOSDs.
Phase:
Phase 2
Details
Lead Sponsor:
Xuanwu Hospital, Beijing
Treatments:
Zanubrutinib